Press Releases for the Psychedelics Industry

Psychedelics News

Press Releases

29 Mar 2021

Algernon Pharmaceuticals Announces its Addition to the Market’s First Psychedelic Stock Index ETF

VANCOUVER, British Columbia....

By Microdose

Press Releases

29 Mar 2021

Lobe Sciences Added to Horizons Psychedelic Stock Index ETF

Vancouver, British Columbia–(Newsfile Corp....

By Microdose

Press Releases

25 Mar 2021

New Wave Subsidiary, Way of Will Inc., Announces Launch of Functional Mushroom Capsules and Functional Mushroom Powder as Part of New Emerging…

TORONTO, March 25, 2021 /CNW/ - NEW WAVE HOLDINGS CORP....

By Microdose

Press Releases

24 Mar 2021

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

23 Mar 2021

Mindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform (“Cope”); Cope Expected to Be World’s First in Vivo Psychedelic Benchmark Data Set

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

23 Mar 2021

NeonMind CEO Provides Update on the Progress of its Psilocybin Drug Development Research Plan and Team

Vancouver, British Columbia–(Newsfile Corp....

By Microdose

Press Releases

22 Mar 2021

MindMed Announces Inclusion in FTSE Russell Indexes

NEW YORKMarch 22, 2021 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company announced that effective as of Friday March 19th, 2021, MindMed has...

By Microdose

Press Releases

19 Mar 2021

Numinus Announces Closing of $40-Million Bought Deal Financing

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC, March...

By Microdose

Press Releases

19 Mar 2021

Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application

TORONTO, March 19, 2021 – Revive Therapeutics Ltd....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result